Skip to content

Novavax NVAX Short- term Investments

Short- term Investments at other companies

Roivant Sciences logo
Roivant SciencesROIV
Merck & Co. logo
Merck & Co.MRK
Gilead Sciences logo
Gilead SciencesGILD
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's short- term investments?
Novavax (NVAX) reported short- term investments of $561.97M in Q1 2026.
How has Novavax's short- term investments changed year-over-year?
Novavax's short- term investments increased by 20.0% year-over-year, from $468.14M to $561.97M.
What is the long-term trend for Novavax's short- term investments?
Over 4 years (2020 to 2025), Novavax's short- term investments has grown at a 33.1% compound annual growth rate (CAGR), from $157.65M to $494.45M.